The Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular telangiectasia type 2 (MacTel).

Vivani was created in 2022 when subdermal drug implant company Nano Precision Medical merged with implantable visual ...

Vivani Medical, Inc. (NASDAQ:VANI) said it intends to spin off Cortigent, Inc., a division that develops brain implant ...

The US Food and Drug Administration (FDA) has approved Encelto (revakinagene taroretcel-lwey) for the treatment of macular ...

With a U.S. green light for its encapsulated cell therapy technology in the bag, privately held biotech Neurotech ...

In addition to comparable BCVA levels, the researchers concluded that the PDS implant “provides effective, durable, and ...

The FDA has approved Susvimo (ranibizumab injection) for the treatment of patients with diabetic macular edema.

ENCELTO is the First and Only FDA-approved Treatment for MacTel. CUMBERLAND, RI, USA I March 06, 2025 I Neurotech Pharmaceuticals, Inc., a private biotech company focused on d ...

A rare, progressive neurodegenerative disease associated with loss of macular photoreceptors in the retinas, MacTel type 2 ...

THINK Surgical, Inc., an innovator in the field of orthopedic surgical robots, today announced the successful first use of Waldemar Link's (LINK) LinkSymphoKnee utilizing THINK Surgical's TMINI® ...

Perfuse Therapeutics has reported 24-week data from its Phase I/IIa trial of the PER-001 intravitreal implant for individuals ...